SystmOne Aminosalicylate drug monitoring template and patient letter have been updated to include the latest MHRA safety warning about the rare risk of idiopathic intracranial hypertension (IIH) with mesalazine. Patients are now clearly advised on symptoms to report urgently, such as persistent headache, visual changes, or tinnitus.